Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Adapalene Clear all
Completed Phase 4 Interventional Results available

A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne

NCT01231334
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone plus Adapalene, Clindamycin/benzoyl peroxide plus Adapalene
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 3, 2026, 5:31 AM EDT
Recruiting Phase 1 Interventional

CD4^LVFOXP3 in Participants With IPEX

NCT05241444
View directory record Official record
Conditions
IPEX
Interventions
CD4^LVFOXP3
Biological
Lead sponsor
Bacchetta, Rosa, MD
Other
Eligibility
4 Months to 35 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2037
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris

NCT02249104
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene/benzoyl peroxide gel, 0.1%/2.5%, Cetaphil Acne Regimen
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 3, 2026, 5:31 AM EDT
Recruiting Phase 4 Interventional

Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo

NCT07524946
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CABTREO is a fixed-combination product of clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15%.
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Bryant, Arkansas • Rogers, Arkansas • Freemont, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris

NCT00441415
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene BPO
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Santa Monica, California • Fridley, Minnesota • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 4 Interventional

Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%

NCT00437151
View directory record Official record
Conditions
Acne
Interventions
More frequent than normal office visits, Electronic reminders (voice, e-mail, text messages), Parenteral involvement / intervention reminders, No intervention or reminders
Other
Lead sponsor
Galderma R&D
Industry
Eligibility
13 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne

NCT00964223
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin and benzoyl peroxide gel (Duac® Topical Gel), benzoyl peroxide and adapalene gel (EPIDUO™ Gel)
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Rockville, Maryland • Warren, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage

NCT00647556
View directory record Official record
Conditions
Photoaging
Interventions
adapalene gel, 0.3%, tretinoin 0.05% emollient cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

NCT03650361
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo
Drug
Lead sponsor
Aleor Dermaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

NCT02651220
View directory record Official record
Conditions
Acne
Interventions
Epiduo® Forte Gel, Adapalene and Benzoyl Peroxide Gel, placebo gel
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,001 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
18
States / cities
Mesa, Arizona • Tucson, Arizona • Anaheim, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel

NCT01522456
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Epiduo Gel, Retin-A Micro Microsphere 0.1%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris

NCT00696449
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene, frequent visits, electronic reminder, Parent reminder, Standard of care
Drug · Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
13 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 3, 2026, 5:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Lipid Profile of the Skin Surface in Acne

NCT02180425
View directory record Official record
Conditions
Acne
Interventions
Tretinoin or Adapalene, Isotretinoin
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
Davis, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

Combination Therapy With Differin® Gel 0.3% and Duac® (Clindamycin/Benzoyl Peroxide Gel) in Subjects With Acne Vulgaris

NCT00671749
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene gel, 0.3%, clindamycin/benzoyl peroxide gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Sacramento, California • Louisville, Kentucky • Warren, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

Effect of Samples on Acne Treatment With Epiduo® Gel

NCT01504204
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene + benzoyl peroxide samples, Adapalene + benzoyl peroxide from standard tube
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 3, 2026, 5:31 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00829049
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Cream 0.1%, Adapalene
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne

NCT06336603
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Winlevi (clascoterone) 1% & Adapalene 0.3% gel
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

NCT00598832
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene lotion 0.1%, Adapalene Lotion Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,075 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Marina del Rey, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Irritation That Potentially Could be Caused by Two Facial Gels Applied to Opposite Sides of the Face

NCT00952523
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Facial Gel, Adapalene/Benzoyl Peroxide Facial Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

NCT00422240
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene/Benzoyl Peroxide, Adapalene Gel, 0.1%, Benzoyl Peroxide Gel 2.5%, Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2024 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments

NCT02755545
View directory record Official record
Conditions
Acne
Interventions
Product A, Product B
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
21 Years to 45 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tolerability Comparison of Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin

NCT01046396
View directory record Official record
Conditions
Skin Manifestations
Interventions
adapalene cream 0.1% and adapalene lotion 0.1%, adapalene lotion 0.1%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 3, 2026, 5:31 AM EDT
Withdrawn Phase 3 Interventional

MC RCT - BPO vs Adapalene

NCT05536882
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
Benzoyl peroxide, Adapalene Gel
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
1 Year to 14 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 3, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin

NCT01046565
View directory record Official record
Conditions
Skin Manifestations
Interventions
adapalene cream 0.1%, adapalene lotion 0.1%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Sep 3, 2026, 5:31 AM EDT